HDAC inhibitor-based therapies: Can we interpret the code?

Molecular Oncology

Volumn 6, Issue 6, 2012, Pages 637-656

  New, Maria ^a   Olzscha, Heidi ^a   La Thangue, Nicholas B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acetylation; Biomarkers; Cancer; Drugs epigenetics; HDAC

Indexed keywords

ABEXINOSTAT; BELINOSTAT; BETA CATENIN; BUTYRIC ACID; CASPASE 8; CASPASE 9; CYTOCHROME C; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; GIVINOSTAT; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; MOCETINOSTAT; PANOBINOSTAT; RESMINOSTAT; RETINOIC ACID; ROMIDEPSIN; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EPIGENETICS; EPILEPSY; EXCISION REPAIR; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HISTONE ACETYLATION; HODGKIN DISEASE; HUMAN; IMMUNITY; INFLAMMATION; KIDNEY CANCER; MITOSIS; MULTIPLE MYELOMA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEOSOME; ONCOGENE; PLEIOTROPY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; REVIEW; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

EID: 84869869682     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.09.003     Document Type: Review

References (210)

1. Adimoolam S., Sirisawad M., Chen J., Thiemann P., Ford J.M., Buggy J.J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl. Acad. Sci. U S A 2007, 104:19482-19487.
2. Arts J., Angibaud P., Marien A., Floren W., Janssens B., King P., van Dun J., Janssen L., Geerts T., Tuman R.W., Johnson D.L., Andries L., Jung M., Janicot M., van Emelen K. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br. J. Cancer 2007, 97:1344-1353.
3. Badros A., Burger A.M., Philip S., Niesvizky R., Kolla S.S., Goloubeva O., Harris C., Zwiebel J., Wright J.J., Espinoza-Delgado I., Baer M.R., Holleran J.L., Egorin M.J., Grant S. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin. Cancer Res. 2009, 15:5250-5257.
4. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421:499-506.
5. Balch W.E., Morimoto R.I., Dillin A., Kelly J.W. Adapting proteostasis for disease intervention. Science 2008, 319:916-919.
6. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., Rocha K., Kumaraswamy S., Boyapalle S., Atadja P., Seto E., Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 2005, 280:26729-26734.
7. Bantscheff M., Hopf C., Savitski M.M., Dittmann A., Grandi P., Michon A.M., Schlegl J., Abraham Y., Becher I., Bergamini G., Boesche M., Delling M., Dumpelfeld B., Eberhard D., Huthmacher C., Mathieson T., Poeckel D., Reader V., Strunk K., Sweetman G., Kruse U., Neubauer G., Ramsden N.G., Drewes G. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 2011, 29:255-265.
8. Behrends C., Sowa M.E., Gygi S.P., Harper J.W. Network organization of the human autophagy system. Nature 2010, 466:68-76.
9. Bentley G.A., Finch J.T., Lewit-Bentley A., Roth M. The crystal structure of the nucleosome core particle by contrast variation. Basic Life Sci. 1984, 27:105-117.
10. Bhalla S., Balasubramanian S., David K., Sirisawad M., Buggy J., Mauro L., Prachand S., Miller R., Gordon L.I., Evens A.M. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin. Cancer Res. 2009, 15:3354-3365.
11. Bhaskara S., Chyla B.J., Amann J.M., Knutson S.K., Cortez D., Sun Z.W., Hiebert S.W. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol. Cell 2008, 30:61-72.
12. Bjorkoy G., Lamark T., Brech A., Outzen H., Perander M., Overvatn A., Stenmark H., Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 2005, 171:603-614.
13. Blattmann C., Oertel S., Ehemann V., Thiemann M., Huber P.E., Bischof M., Witt O., Deubzer H.E., Kulozik A.E., Debus J., Weber K.J. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78:237-245.
14. Bode K.A., Schroder K., Hume D.A., Ravasi T., Heeg K., Sweet M.J., Dalpke A.H. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007, 122:596-606.
15. Bolderson E., Richard D.J., Zhou B.B., Khanna K.K. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin. Cancer Res. 2009, 15:6314-6320.
16. Bommareddy A., Hahm E.R., Xiao D., Powolny A.A., Fisher A.L., Jiang Y., Singh S.V. Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res. 2009, 69:3704-3712.
17. Borbone E., Berlingieri M.T., De Bellis F., Nebbioso A., Chiappetta G., Mai A., Altucci L., Fusco A. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 2010, 29:105-116.
18. Boumber Y., Younes A., Garcia-Manero G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin. Investig. Drugs 2011, 20:823-829.
19. Boyault C., Zhang Y., Fritah S., Caron C., Gilquin B., Kwon S.H., Garrido C., Yao T.P., Vourc'h C., Matthias P., Khochbin S. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev. 2007, 21:2172-2181.
20. Brogdon J.L., Xu Y., Szabo S.J., An S., Buxton F., Cohen D., Huang Q. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007, 109:1123-1130.
21. Bruzzese F., Leone A., Rocco M., Carbone C., Piro G., Caraglia M., Di Gennaro E., Budillon A. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J. Cell. Physiol. 2011, 226:2378-2390.
22. Buglio D., Khaskhely N.M., Voo K.S., Martinez-Valdez H., Liu Y.J., Younes A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 2011, 117:2910-2917.
23. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., Lin T.S., Liu S.J., Sklenar A.R., Davis M.E., Lucas D.M., Fischer B., Shank R., Tejaswi S.L., Binkley P., Wright J., Chan K.K., Grever M.R. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105:959-967.
24. Camphausen K., Tofilon P.J. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol. 2007, 25:4051-4056.
25. Carew J.S., Medina E.C., Esquivel J.A., Mahalingam D., Swords R., Kelly K., Zhang H., Huang P., Mita A.C., Mita M.M., Giles F.J., Nawrocki S.T. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J. Cell. Mol. Med. 2010, 14:2448-2459.
26. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
27. Cha T.L., Chuang M.J., Wu S.T., Sun G.H., Chang S.Y., Yu D.S., Huang S.M., Huan S.K., Cheng T.C., Chen T.T., Fan P.L., Hsiao P.W. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin. Cancer Res. 2009, 15:840-850.
28. Chalkiadaki A., Guarente L. Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat. Rev. Endocrinol. 2012, 8:287-296.
29. Chang H.M., Paulson M., Holko M., Rice C.M., Williams B.R., Marie I., Levy D.E. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl. Acad. Sci. U S A 2004, 101:9578-9583.
30. Chavez-Blanco A., Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Cetina L., Candelaria M., Cantu D., Gonzalez-Fierro A., Garcia-Lopez P., Zambrano P., Perez-Plasencia C., Cabrera G., Trejo-Becerril C., Angeles E., Duenas-Gonzalez A. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol. Cancer 2005, 4:22.
31. Chinnaiyan P., Vallabhaneni G., Armstrong E., Huang S.M., Harari P.M. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:223-229.
32. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., Olsen J.V., Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
33. Coiffier B., Pro B., Prince H.M., Foss F.M., Sokol L., Greenwood M., Caballero D., Borchmann P., Morschhauser F., Wilhelm M., Pinter-Brown L., Padmanabhan S., Shustov A.R., Nichols J., Carroll S., Balser J., Horwitz S.M. Analysis of patients with common peripheral T-cell lymphoma subtypes from a phase 2 study of romidepsin in relapsed or refractory peripheral T-cell lymphoma. Blood 2011, 118:272.
34. Cramer T., Yamanishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., Haase V.H., Jaenisch R., Corr M., Nizet V., Firestein G.S., Gerber H.P., Ferrara N., Johnson R.S. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003, 112:645-657.
35. Dai C., Whitesell L., Rogers A.B., Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007, 130:1005-1018.
36. Dai Y., Rahmani M., Dent P., Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol. Cell. Biol. 2005, 25:5429-5444.
37. Dasmahapatra G., Lembersky D., Son M.P., Attkisson E., Dent P., Fisher R.I., Friedberg J.W., Grant S. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol. Cancer Ther. 2011, 10:1686-1697.
38. de Bono J.S., Kristeleit R., Tolcher A., Fong P., Pacey S., Karavasilis V., Mita M., Shaw H., Workman P., Kaye S., Rowinsky E.K., Aherne W., Atadja P., Scott J.W., Patnaik A. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14:6663-6673.
39. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370:737-749.
40. De Schutter H., Kimpe M., Isebaert S., Nuyts S. A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73:904-912.
41. Deorukhkar A., Shentu S., Park H.C., Diagaradjane P., Puduvalli V., Aggarwal B., Guha S., Krishnan S. Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells. Pancreas 2010, 39:1277-1283.
42. Dequiedt F., Kasler H., Fischle W., Kiermer V., Weinstein M., Herndier B.G., Verdin E. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003, 18:687-698.
43. Dequiedt F., Van Lint J., Lecomte E., Van Duppen V., Seufferlein T., Vandenheede J.R., Wattiez R., Kettmann R. Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis. J. Exp. Med. 2005, 201:793-804.
44. Dowdy S.C., Jiang S., Zhou X.C., Hou X., Jin F., Podratz K.C., Jiang S.W. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol. Cancer Ther. 2006, 5:2767-2776.
45. Eot-Houllier G., Fulcrand G., Magnaghi-Jaulin L., Jaulin C. Histone deacetylase inhibitors and genomic instability. Cancer Lett. 2009, 274:169-176.
46. Fantin V.R., Loboda A., Paweletz C.P., Hendrickson R.C., Pierce J.W., Roth J.A., Li L., Gooden F., Korenchuk S., Hou X.S., Harrington E.A., Randolph S., Reilly J.F., Ware C.M., Kadin M.E., Frankel S.R., Richon V.M. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008, 68:3785-3794.
47. FDA FDA Approves Drug Treatment for Rare Cancer 2009, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm189629.htm.
48. Feng R., Oton A., Mapara M.Y., Anderson G., Belani C., Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br. J. Haematol. 2007, 139:385-397.
49. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401:188-193.
50. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604-4613.
51. Foster S.L., Hargreaves D.C., Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007, 447:972-978.
52. Fotheringham S., Epping M.T., Stimson L., Khan O., Wood V., Pezzella F., Bernards R., La Thangue N.B. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009, 15:57-66.
53. Fournel M., Bonfils C., Hou Y., Yan P.T., Trachy-Bourget M.C., Kalita A., Liu J., Lu A.H., Zhou N.Z., Robert M.F., Gillespie J., Wang J.J., Ste-Croix H., Rahil J., Lefebvre S., Moradei O., Delorme D., Macleod A.R., Besterman J.M., Li Z. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 2008, 7:759-768.
54. Frew A.J., Lindemann R.K., Martin B.P., Clarke C.J., Sharkey J., Anthony D.A., Banks K.M., Haynes N.M., Gangatirkar P., Stanley K., Bolden J.E., Takeda K., Yagita H., Secrist J.P., Smyth M.J., Johnstone R.W. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc. Natl. Acad. Sci. U S A 2008, 105:11317-11322.
55. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets 2008, 8:132-140.
56. Gao Y.S., Hubbert C.C., Lu J., Lee Y.S., Lee J.Y., Yao T.P. Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol. Cell. Biol. 2007, 27:8637-8647.
57. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., Faderl S., Koller C., Morris G., Rosner G., Loboda A., Fantin V.R., Randolph S.S., Hardwick J.S., Reilly J.F., Chen C., Ricker J.L., Secrist J.P., Richon V.M., Frankel S.R., Kantarjian H.M. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066.
58. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2003, 2:151-163.
59. Gore S.D., Baylin S., Sugar E., Carraway H., Miller C.B., Carducci M., Grever M., Galm O., Dauses T., Karp J.E., Rudek M.A., Zhao M., Smith B.D., Manning J., Jiemjit A., Dover G., Mays A., Zwiebel J., Murgo A., Weng L.J., Herman J.G. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006, 66:6361-6369.
60. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20:6969-6978.
61. Grayson D.R., Kundakovic M., Sharma R.P. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?. Mol. Pharmacol. 2010, 77:126-135.
62. Gregoretti I.V., Lee Y.M., Goodson H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 2004, 338:17-31.
63. Guerrant W., Patil V., Canzoneri J.C., Oyelere A.K. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J. Med. Chem. 2012, 55:1465-1477.
64. Guo J.Y., Chen H.Y., Mathew R., Fan J., Strohecker A.M., Karsli-Uzunbas G., Kamphorst J.J., Chen G., Lemons J.M., Karantza V., Coller H.A., Dipaola R.S., Gelinas C., Rabinowitz J.D., White E. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011, 25:460-470.
65. Haberland M., Johnson A., Mokalled M.H., Montgomery R.L., Olson E.N. Genetic dissection of histone deacetylase requirement in tumor cells. Proc. Natl. Acad. Sci. U S A 2009, 106:7751-7755.
66. Haigis M.C., Sinclair D.A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 2010, 5:253-295.
67. Halili M.A., Andrews M.R., Labzin L.I., Schroder K., Matthias G., Cao C., Lovelace E., Reid R.C., Le G.T., Hume D.A., Irvine K.M., Matthias P., Fairlie D.P., Sweet M.J. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J. Leukoc. Biol. 2010, 87:1103-1114.
68. Harrison S.J., Quach H., Yuen K., Strayer A., Copeman M.C., Peinert S., Bishton M., Wolf M., Januszewicz H., Kencaly M., Herbert K., Westerman D., Carney D., Seymour J.F., Johnstone R.W., Ritchie D., Prince M. High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial. Blood 2008, 112:1267.
69. Hartl F.U., Bracher A., Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature 2011, 475:324-332.
70. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 2009, 43:67-93.
71. Hippert M.M., O'Toole P.S., Thorburn A. Autophagy in cancer: good, bad, or both?. Cancer Res. 2006, 66:9349-9351.
72. Hrebackova J., Hrabeta J., Eckschlager T. Valproic acid in the complex therapy of malignant tumors. Curr. Drug Targets 2010, 11:361-379.
73. Hrzenjak A., Kremser M.L., Strohmeier B., Moinfar F., Zatloukal K., Denk H. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J. Pathol. 2008, 216:495-504.
74. Huang X., Wang S., Lee C.K., Yang X., Liu B. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Lett. 2011, 307:72-79.
75. Hurwitz J.L., Stasik I., Kerr E.M., Holohan C., Redmond K.M., McLaughlin K.M., Busacca S., Barbone D., Broaddus V.C., Gray S.G., O'Byrne K.J., Johnston P.G., Fennell D.A., Longley D.B. Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. Eur. J. Cancer 2012, 48:1096-1107.
76. Inche A.G., La Thangue N.B. Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov. Today 2006, 11:97-109.
77. Into T., Inomata M., Niida S., Murakami Y., Shibata K. Regulation of MyD88 aggregation and the MyD88-dependent signaling pathway by sequestosome 1 and histone deacetylase 6. J. Biol. Chem. 2010, 285:35759-35769.
78. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
79. Janku F., McConkey D.J., Hong D.S., Kurzrock R. Autophagy as a target for anticancer therapy. Nat. Rev. Clin. Oncol. 2011, 8:528-539.
80. Johnston J.A., Ward C.L., Kopito R.R. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 1998, 143:1883-1898.
81. Kachhap S.K., Rosmus N., Collis S.J., Kortenhorst M.S., Wissing M.D., Hedayati M., Shabbeer S., Mendonca J., Deangelis J., Marchionni L., Lin J., Hoti N., Nortier J.W., DeWeese T.L., Hammers H., Carducci M.A. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One 2010, 5:e11208.
82. Kalac M., Scotto L., Marchi E., Amengual J., Seshan V.E., Bhagat G., Ulahannan N., Leshchenko V.V., Temkin A.M., Parekh S., Tycko B., O'Connor O.A. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 2011, 118:5506-5516.
83. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115:727-738.
84. Khan O., Fotheringham S., Wood V., Stimson L., Zhang C., Pezzella F., Duvic M., Kerr D.J., La Thangue N.B. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Natl. Acad. Sci. U S A 2010, 107:6532-6537.
85. Khan O., La Thangue N.B. Drug insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat. Clin. Pract. Oncol. 2008, 5:714-726.
86. Khan O., La Thangue N.B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 2012, 90:85-94.
87. Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.W., Moon E.J., Kim H.S., Lee S.K., Chung H.Y., Kim C.W., Kim K.W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 2001, 7:437-443.
88. Kim S.H., Jeong J.W., Park J.A., Lee J.W., Seo J.H., Jung B.K., Bae M.K., Kim K.W. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol. Rep. 2007, 17:647-651.
89. Kirschbaum M.H., Goldman B.H., Zain J.M., Cook J.R., Rimsza L.M., Forman S.J., Fisher R.I. Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517. Blood 2007, 110:759a.
90. Kirschbaum M.H., Zain J.M., Popplewell L., Pullarkat V., Nademanee A.P., Delioukina M.L., Pulone B., Matsuoka D., Frankel P., James Z.A., Forman S.J., Newman E., Gandara D. A phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non Hodgkin lymphoma. A California cancer consortium study. Blood 2007, 110:757a.
91. Klampfer L., Huang J., Swaby L.A., Augenlicht L. Requirement of histone deacetylase activity for signaling by STAT1. J. Biol. Chem. 2004, 279:30358-30368.
92. Klimek V.M., Fircanis S., Maslak P., Guernah I., Baum M., Wu N., Panageas K., Wright J.J., Pandolfi P.P., Nimer S.D. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 2008, 14:826-832.
93. Kong X., Fang M., Li P., Fang F., Xu Y. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells. J. Mol. Cell. Cardiol. 2009, 46:292-299.
94. Kong X., Lin Z., Liang D., Fath D., Sang N., Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol. Cell. Biol. 2006, 26:2019-2028.
95. Konstantinopoulos P.A., Vandoros G.P., Papavassiliou A.G. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother. Pharmacol. 2006, 58:711-715.
96. Kotian S., Liyanarachchi S., Zelent A., Parvin J.D. Histone deacetylases 9 and 10 are required for homologous recombination. J. Biol. Chem. 2011, 286:7722-7726.
97. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., Yoshida M., Toft D.O., Pratt W.B., Yao T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 2005, 18:601-607.
98. Kramer O.H., Knauer S.K., Greiner G., Jandt E., Reichardt S., Guhrs K.H., Stauber R.H., Bohmer F.D., Heinzel T. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 2009, 23:223-235.
99. Krusche C.A., Wulfing P., Kersting C., Vloet A., Bocker W., Kiesel L., Beier H.M., Alfer J. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treat. 2005, 90:15-23.
100. Kuendgen A., Schmid M., Schlenk R., Knipp S., Hildebrandt B., Steidl C., Germing U., Haas R., Dohner H., Gattermann N. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106:112-119.
101. La Thangue N.B., Kerr D.J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 2011, 8:587-596.
102. Lee J.Y., Koga H., Kawaguchi Y., Tang W., Wong E., Gao Y.S., Pandey U.B., Kaushik S., Tresse E., Lu J., Taylor J.P., Cuervo A.M., Yao T.P. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J. 2010, 29:969-980.
103. Lee Y.S., Lim K.H., Guo X., Kawaguchi Y., Gao Y., Barrientos T., Ordentlich P., Wang X.F., Counter C.M., Yao T.P. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 2008, 68:7561-7569.
104. Leoni F., Fossati G., Lewis E.C., Lee J.K., Porro G., Pagani P., Modena D., Moras M.L., Pozzi P., Reznikov L.L., Siegmund B., Fantuzzi G., Dinarello C.A., Mascagni P. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 2005, 11:1-15.
105. Li Y., Zhang X., Polakiewicz R.D., Yao T.P., Comb M.J. HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. J. Biol. Chem. 2008, 283:12686-12690.
106. Lian Z.R., Xu Y.F., Wang X.B., Gong J.P., Liu Z.J. Suppression of histone deacetylase 11 promotes expression of IL-10 in kupffer cells and induces tolerance following orthotopic liver transplantation in rats. J. Surg. Res. 2012, 174:359-368.
107. Liu T., Liu P.Y., Marshall G.M. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009, 69:1702-1705.
108. Lorin S., Borges A., Ribeiro Dos Santos L., Souquere S., Pierron G., Ryan K.M., Codogno P., Djavaheri-Mergny M. c-Jun NH2-terminal kinase activation is essential for DRAM-dependent induction of autophagy and apoptosis in 2-methoxyestradiol-treated Ewing sarcoma cells. Cancer Res. 2009, 69:6924-6931.
109. Lu J., Sun H., Wang X., Liu C., Xu X., Li F., Huang B. Interleukin-12 p40 promoter activity is regulated by the reversible acetylation mediated by HDAC1 and p300. Cytokine 2005, 31:46-51.
110. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2007, 8:741-752.
111. Marchion D.C., Bicaku E., Turner J.G., Schmitt M.L., Morelli D.R., Munster P.N. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol. Cancer Ther. 2009, 8:794-801.
112. Marks P.A. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs 2010, 19:1049-1066.
113. Marquard L., Gjerdrum L.M., Christensen I.J., Jensen P.B., Sehested M., Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008, 53:267-277.
114. Martinez-Balbas M.A., Bauer U.M., Nielsen S.J., Brehm A., Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J. 2000, 19:662-671.
115. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W., Ratcliffe P.J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U S A 1997, 94:8104-8109.
116. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
117. Miller K.M., Tjeertes J.V., Coates J., Legube G., Polo S.E., Britton S., Jackson S.P. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat. Struct. Mol. Biol. 2010, 17:1144-1151.
118. Minamiya Y., Ono T., Saito H., Takahashi N., Ito M., Mitsui M., Motoyama S., Ogawa J. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2011, 74:300-304.
119. Miyake K., Yoshizumi T., Imura S., Sugimoto K., Batmunkh E., Kanemura H., Morine Y., Shimada M. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008, 36:e1-e9.
120. Moehler T.M., Neben K., Ho A.D., Goldschmidt H. Angiogenesis in hematologic malignancies. Ann. Hematol. 2001, 80:695-705.
121. Mohammed T.A., Holen K.D., Jaskula-Sztul R., Mulkerin D., Lubner S.J., Schelman W.R., Eickhoff J., Chen H., Loconte N.K. A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist 2011, 16:835-843.
122. Molife L.R., Attard G., Fong P.C., Karavasilis V., Reid A.H., Patterson S., Riggs C.E., Higano C., Stadler W.M., McCulloch W., Dearnaley D., Parker C., de Bono J.S. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann. Oncol. 2010, 21:109-113.
123. Moniot S., Weyand M., Steegborn C. Structures, substrates, and regulators of Mammalian sirtuins - opportunities and challenges for drug development. Front. Pharmacol. 2012, 3:16.
124. Montgomery R.L., Davis C.A., Potthoff M.J., Haberland M., Fielitz J., Qi X., Hill J.A., Richardson J.A., Olson E.N. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 2007, 21:1790-1802.
125. Morselli E., Tasdemir E., Maiuri M.C., Galluzzi L., Kepp O., Criollo A., Vicencio J.M., Soussi T., Kroemer G. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008, 7:3056-3061.
126. Mottet D., Pirotte S., Lamour V., Hagedorn M., Javerzat S., Bikfalvi A., Bellahcene A., Verdin E., Castronovo V. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 2009, 28:243-256.
127. Mueller S., Yang X., Sottero T.L., Gragg A., Prasad G., Polley M.Y., Weiss W.A., Matthay K.K., Davidoff A.M., DuBois S.G., Haas-Kogan D.A. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett. 2011, 306:223-229.
128. Munster P.N., Daud A.I. Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Expert Opin. Investig. Drugs 2011, 20:1565-1574.
129. Nakagawa M., Oda Y., Eguchi T., Aishima S., Yao T., Hosoi F., Basaki Y., Ono M., Kuwano M., Tanaka M., Tsuneyoshi M. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 2007, 18:769-774.
130. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., Alvarez R., Schiavone E.M., Ferrara F., Bresciani F., Weisz A., de Lera A.R., Gronemeyer H., Altucci L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005, 11:77-84.
131. Nguyen T., Dai Y., Attkisson E., Kramer L., Jordan N., Nguyen N., Kolluri N., Muschen M., Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin. Cancer Res. 2011, 17:3219-3232.
132. Niesvizky R., Ely S., Mark T., Aggarwal S., Gabrilove J.L., Wright J.J., Chen-Kiang S., Sparano J.A. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011, 117:336-342.
133. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., Moscinski L., Smith C., Wu J., Jove R., Atadja P., Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003, 63:5126-5135.
134. Nolan L., Johnson P.W., Ganesan A., Packham G., Crabb S.J. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?. Br. J. Cancer 2008, 99:689-694.
135. Noro R., Miyanaga A., Minegishi Y., Okano T., Seike M., Soeno C., Kataoka K., Matsuda K., Yoshimura A., Gemma A. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression. Cancer Sci. 2010, 101:1424-1430.
136. Nusinzon I., Horvath C.M. Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation. Mol. Cell. Biol. 2006, 26:3106-3113.
137. O'Connor O.A., Heaney M.L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., Curly T., Moskowitz C., Portlock C., Horwitz S., Zelenetz A.D., Frankel S., Richon V., Marks P., Kelly W.K. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 2006, 24:166-173.
138. Oehme I., Deubzer H.E., Lodrini M., Milde T., Witt O. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin. Investig. Drugs 2009, 18:1605-1617.
139. Olzmann J.A., Li L., Chudaev M.V., Chen J., Perez F.A., Palmiter R.D., Chin L.S. Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J. Cell Biol. 2007, 178:1025-1038.
140. Osada H., Tatematsu Y., Saito H., Yatabe Y., Mitsudomi T., Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int. J. Cancer 2004, 112:26-32.
141. Ozdag H., Teschendorff A.E., Ahmed A.A., Hyland S.J., Blenkiron C., Bobrow L., Veerakumarasivam A., Burtt G., Subkhankulova T., Arends M.J., Collins V.P., Bowtell D., Kouzarides T., Brenton J.D., Caldas C. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006, 7:90.
142. Park J.H., Kim S.H., Choi M.C., Lee J., Oh D.Y., Im S.A., Bang Y.J., Kim T.Y. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem. Biophys. Res. Commun. 2008, 368:318-322.
143. Petruccelli L.A., Dupere-Richer D., Pettersson F., Retrouvey H., Skoulikas S., Miller W.H. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS One 2011, 6:e20987.
144. Peyssonnaux C., Cejudo-Martin P., Doedens A., Zinkernagel A.S., Johnson R.S., Nizet V. Cutting edge: essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. J. Immunol. 2007, 178:7516-7519.
145. Piekarz R.L., Frye R., Prince H.M., Kirschbaum M.H., Zain J., Allen S.L., Jaffe E.S., Ling A., Turner M., Peer C.J., Figg W.D., Steinberg S.M., Smith S., Joske D., Lewis I., Hutchins L., Craig M., Fojo A.T., Wright J.J., Bates S.E. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117:5827-5834.
146. Pili R., Salumbides B., Zhao M., Altiok S., Qian D., Zwiebel J., Carducci M.A., Rudek M.A. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br. J. Cancer 2012, 106:77-84.
147. Plumb J.A., Finn P.W., Williams R.J., Bandara M.J., Romero M.R., Watkins C.J., La Thangue N.B., Brown R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 2003, 2:721-728.
148. Pohlman B., Advani R., Duvic M., Hymes K.B., Intragumtornchai T., Lekhakula A., Shpilberg O., Lerner A., Ben-Yehuda D., Beylot-Barry M., Hillen U., Fagerberg J., Foss F.M. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood 2009, 114:379.
149. Qian D.Z., Kachhap S.K., Collis S.J., Verheul H.M., Carducci M.A., Atadja P., Pili R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 2006, 66:8814-8821.
150. Ramalingam S.S., Maitland M.L., Frankel P., Argiris A.E., Koczywas M., Gitlitz B., Thomas S., Espinoza-Delgado I., Vokes E.E., Gandara D.R., Belani C.P. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:56-62.
151. Rao R., Fiskus W., Yang Y., Lee P., Joshi R., Fernandez P., Mandawat A., Atadja P., Bradner J.E., Bhalla K. HDAC6 inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008, 112:1886-1893.
152. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O'Kane C.J., Rubinsztein D.C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.
153. Richardson P., Mitsiades C., Colson K., Reilly E., McBride L., Chiao J., Sun L., Ricker J., Rizvi S., Oerth C., Atkins B., Fearen I., Anderson K., Siegel D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma. 2008, 49:502-507.
154. Richon V.M., Garcia-Vargas J., Hardwick J.S. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009, 280:201-210.
155. Rikiishi H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J. Biomed. Biotechnol. 2011, 2011:830260.
156. Rodriguez-Rocha H., Garcia-Garcia A., Panayiotidis M.I., Franco R. DNA damage and autophagy. Mutat. Res. 2011, 711:158-166.
157. Roger T., Lugrin J., Le Roy D., Goy G., Mombelli M., Koessler T., Ding X.C., Chanson A.L., Reymond M.K., Miconnet I., Schrenzel J., Francois P., Calandra T. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011, 117:1205-1217.
158. Ropero S., Fraga M.F., Ballestar E., Hamelin R., Yamamoto H., Boix-Chornet M., Caballero R., Alaminos M., Setien F., Paz M.F., Herranz M., Palacios J., Arango D., Orntoft T.F., Aaltonen L.A., Schwartz S., Esteller M. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 2006, 38:566-569.
159. Rosato R.R., Almenara J.A., Dai Y., Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2003, 2:1273-1284.
160. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
161. Sasaki H., Moriyama S., Nakashima Y., Kobayashi Y., Kiriyama M., Fukai I., Yamakawa Y., Fujii Y. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004, 46:171-178.
162. Satoh A., Stein L., Imai S. The role of mammalian sirtuins in the regulation of metabolism, aging, and longevity. Handb. Exp. Pharmacol. 2011, 206:125-162.
163. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
164. Shao Y., Gao Z., Marks P.A., Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U S A 2004, 101:18030-18035.
165. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
166. Stadler W.M., Margolin K., Ferber S., McCulloch W., Thompson J.A. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 2006, 5:57-60.
167. Steele N.L., Plumb J.A., Vidal L., Tjornelund J., Knoblauch P., Rasmussen A., Ooi C.E., Buhl-Jensen P., Brown R., Evans T.R., DeBono J.S. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14:804-810.
168. Stevens F.E., Beamish H., Warrener R., Gabrielli B. Histone deacetylase inhibitors induce mitotic slippage. Oncogene 2008, 27:1345-1354.
169. Stimson L., La Thangue N.B. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett. 2009, 280:177-183.
170. Stimson L., Wood V., Khan O., Fotheringham S., La Thangue N.B. HDAC inhibitor-based therapies and haematological malignancy. Ann. Oncol. 2009, 20:1293-1302.
171. Sudo T., Mimori K., Nishida N., Kogo R., Iwaya T., Tanaka F., Shibata K., Fujita H., Shirouzu K., Mori M. Histone deacetylase 1 expression in gastric cancer. Oncol. Rep. 2011, 26:777-782.
172. Sun X., Wei L., Chen Q., Terek R.M. HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity. J. Biol. Chem. 2009, 284:21881-21890.
173. Taddei A., Maison C., Roche D., Almouzni G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat. Cell Biol. 2001, 3:114-120.
174. Tan J.M., Wong E.S., Kirkpatrick D.S., Pletnikova O., Ko H.S., Tay S.P., Ho M.W., Troncoso J., Gygi S.P., Lee M.K., Dawson V.L., Dawson T.M., Lim K.L. Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum. Mol. Genet. 2008, 17:431-439.
175. Tang X., Gao J.S., Guan Y.J., McLane K.E., Yuan Z.L., Ramratnam B., Chin Y.E. Acetylation-dependent signal transduction for type I interferon receptor. Cell 2007, 131:93-105.
176. Theocharis S., Klijanienko J., Giaginis C., Rodriguez J., Jouffroy T., Girod A., Alexandrou P., Sastre-Garau X. Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J. Oral Pathol. Med. 2011, 40:706-714.
177. Tsai H.C., Wei K.C., Tsai C.N., Huang Y.C., Chen P.Y., Chen S.M., Lu Y.J., Lee S.T. Effect of valproic acid on the outcome of glioblastoma multiforme. Br. J. Neurosurg. 2011, 26:347-354.
178. Urbich C., Rossig L., Kaluza D., Potente M., Boeckel J.N., Knau A., Diehl F., Geng J.G., Hofmann W.K., Zeiher A.M., Dimmeler S. HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. Blood 2009, 113:5669-5679.
179. Vega R.B., Matsuda K., Oh J., Barbosa A.C., Yang X., Meadows E., McAnally J., Pomajzl C., Shelton J.M., Richardson J.A., Karsenty G., Olson E.N. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004, 119:555-566.
180. Verdin E., Dequiedt F., Kasler H.G. Class II histone deacetylases: versatile regulators. Trends Genet. 2003, 19:286-293.
181. Verma R., Oania R., Graumann J., Deshaies R.J. Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system. Cell 2004, 118:99-110.
182. Wang Z.H., Xu L., Duan Z.L., Zeng L.Q., Yan N.H., Peng Z.L. Beclin 1-mediated macroautophagy involves regulation of caspase-9 expression in cervical cancer HeLa cells. Gynecol. Oncol. 2007, 107:107-113.
183. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., Rubinsztein D.C. Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 2003, 278:25009-25013.
184. Weber D., Badros A.Z., Jagannath S., Siegel D., Richon V., Rizvi S., Garcia-Vargas J., Reiser D., Anderson K.C. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience. Blood 2008, 112:322.
185. Westerheide S.D., Anckar J., Stevens S.M., Sistonen L., Morimoto R.I. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 2009, 323:1063-1066.
186. White E., DiPaola R.S. The double-edged sword of autophagy modulation in cancer. Clin. Cancer Res. 2009, 15:5308-5316.
187. Whitehead R.P., Rankin C., Hoff P.M., Gold P.J., Billingsley K.G., Chapman R.A., Wong L., Ward J.H., Abbruzzese J.L., Blanke C.D. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest. New Drugs 2009, 27:469-475.
188. Wilson A.J., Byun D.S., Nasser S., Murray L.B., Ayyanar K., Arango D., Figueroa M., Melnick A., Kao G.D., Augenlicht L.H., Mariadason J.M. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol. Biol. Cell. 2008, 19:4062-4075.
189. Wilson A.J., Byun D.S., Popova N., Murray L.B., L'Italien K., Sowa Y., Arango D., Velcich A., Augenlicht L.H., Mariadason J.M. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 2006, 281:13548-13558.
190. Wilting R.H., Yanover E., Heideman M.R., Jacobs H., Horner J., van der Torre J., DePinho R.A., Dannenberg J.H. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 2010, 29:2586-2597.
191. Witt O., Deubzer H.E., Milde T., Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett. 2009, 277:8-21.
192. Wu L.M., Yang Z., Zhou L., Zhang F., Xie H.Y., Feng X.W., Wu J., Zheng S.S. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One 2010, 5:e14460.
193. Xu J., Zhou J.Y., Wei W.Z., Philipsen S., Wu G.S. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res. 2008, 68:6718-6726.
194. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
195. Yamaguchi T., Cubizolles F., Zhang Y., Reichert N., Kohler H., Seiser C., Matthias P. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev. 2010, 24:455-469.
196. Yamamoto S., Tanaka K., Sakimura R., Okada T., Nakamura T., Li Y., Takasaki M., Nakabeppu Y., Iwamoto Y. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res. 2008, 28:1585-1591.
197. Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene, http://dx.doi.org/10.1038/onc.2012.81.
198. Yang S., Wang X., Contino G., Liesa M., Sahin E., Ying H., Bause A., Li Y., Stommel J.M., Dell'antonio G., Mautner J., Tonon G., Haigis M., Shirihai O.S., Doglioni C., Bardeesy N., Kimmelman A.C. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011, 25:717-729.
199. Yang X.J., Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 2008, 9:206-218.
200. Ye F., Chen Y., Hoang T., Montgomery R.L., Zhao X.H., Bu H., Hu T., Taketo M.M., van Es J.H., Clevers H., Hsieh J., Bassel-Duby R., Olson E.N., Lu Q.R. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat. Neurosci. 2009, 12:829-838.
201. Younes A., Bociek R.G., Kuruvilla J., Laneuville P., Fung H.C., Drouin M., Patterson T., Besterman J., Martell R.E. Mocetinostat (MGCD0103), an isotype-selective histone deacetylase (HDAC) inhibitor, produces clinical responses in relapsed/refractory Hodgkin lymphoma (HL): update from a phase II clinical study. Blood 2010, 116:735.
202. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
203. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
204. Yu W., Wang J., Jin J., Qian W., Qian J., Cheng Y., Wang L. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor. Leuk. Res. 2011, 35:1212-1218.
205. Zhang F., Zhang T., Teng Z.H., Zhang R., Wang J.B., Mei Q.B. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol. Ther. 2009, 8:823-831.
206. Zhang H., Kong X., Kang J., Su J., Li Y., Zhong J., Sun L. Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol. Sci. 2009, 110:376-388.
207. Zhang Y., Kwon S., Yamaguchi T., Cubizolles F., Rousseaux S., Kneissel M., Cao C., Li N., Cheng H.L., Chua K., Lombard D., Mizeracki A., Matthias G., Alt F.W., Khochbin S., Matthias P. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol. 2008, 28:1688-1701.
208. Zhu P., Martin E., Mengwasser J., Schlag P., Janssen K.P., Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004, 5:455-463.
209. Zika E., Greer S.F., Zhu X.S., Ting J.P. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol. Cell. Biol. 2003, 23:3091-3102.
210. Zupkovitz G., Tischler J., Posch M., Sadzak I., Ramsauer K., Egger G., Grausenburger R., Schweifer N., Chiocca S., Decker T., Seiser C. Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol. Cell. Biol. 2006, 26:7913-7928.